MIRA-55 Matches Celebrex for Pain Relief in 21-Day Chronic Pain Study
MIRA is trading near its 52-week low of $0.6 (14% above the low) on light trading volume (0.2× avg).
Summary
MIRA reported positive 21-day preclinical results for oral MIRA-55 in chronic inflammatory pain, with pain relief comparable to Celebrex and no observed tolerance, supporting a planned IND submission in Q1 2027.
Key Events · Product Development and Regulatory · MIRA
-
MIRA-55 Hits Celebrex-Level Pain Relief
In a 21-day CFA chronic inflammatory pain study, once-daily oral MIRA-55 significantly reduced mechanical and thermal pain hypersensitivity versus vehicle (p<0.001) and matched celecoxib, with no statistically significant difference between the two treatments.
-
Efficacy Held Without Tolerance
Pain relief was sustained across the full three-week dosing period with no decline in effect. MIRA-55 also reduced inflammation-associated paw swelling to a similar magnitude as celecoxib, with consistent results in male and female animals.
-
IND Submission Targeted for Q1 2027
According to MIRA, the data support advancing MIRA-55 toward a planned IND submission in the first quarter of 2027, subject to remaining preclinical and regulatory work; additional tissue analyses on inflammatory cytokines are underway.
-
Cash and Listing Risk Still Unresolved
The results do not address the going-concern doubt and Nasdaq bid-price deficiency previously disclosed. MIRA-55 remains preclinical, and its safety and efficacy in humans have not been established.
Analysis · MIRA · Life Sciences
MIRA-55 remains preclinical, so revenue and cash flow are unchanged today. What the data do is de-risk the second leg of the pipeline: the compound held pain relief for three weeks without tolerance and matched celecoxib, a bar investors can judge. That supports the planned Q1 2027 IND filing and gives management a second program to point to alongside Ketamir-2. Against a going-concern warning and a Nasdaq bid-price deficiency, however, the company still needs cash before either program reaches patients, so the data improve the story without fixing the balance sheet.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 29.4% of the 1560 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MIRA was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.7M. The 52-week trading range was $0.60 to $1.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.